Journal
PARASITOLOGY RESEARCH
Volume 121, Issue 11, Pages 3073-3082Publisher
SPRINGER
DOI: 10.1007/s00436-022-07659-5
Keywords
Leishmaniasis; Liposomes; Drug delivery system; Parasites
Categories
Ask authors/readers for more resources
Human leishmaniasis is a widespread infectious disease with limited treatment options. Encapsulating therapeutic drugs in liposomes can increase drug concentration in host cells, reduce toxicity, and broaden the therapeutic spectrum.
Human leishmaniasis is a vector-borne, neglected infectious disease that is widely distributed in America, Africa, Europe, and Asia. Current therapy is based on old and toxic drugs, including antimonials, aminoglycosides, and amphotericin. As a neglected disease, investment in the development of new therapeutic molecules is scarce. Considering these aspects, the optimization of treatment through novel delivery systems for current therapeutic agents is an attractive alternative. The encapsulation into liposomes of drugs used in treating leishmaniasis increases the concentration of these molecules in macrophages, which may not only increase the chance of cure but also expand their therapeutic spectrum to include resistant Leishmania, as well as reducing toxicity since the drug is less exposed to healthy cells. The classical example is the liposomal formulation of amphotericin B, a well-established therapeutic option that uses liposomes to decrease the progression of renal failure in patients. However, loading other leishmanicidal drugs into liposomes, such as pentavalent antimonials, presents an opportunity for innovative and cheaper therapeutic options for the treatment of human leishmaniasis. This review aims to discuss liposomes as a drug delivery system for leishmanicidal drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available